- STAT+: A standing ovation for RevMed, and caution for AkesoASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.STAT · 1mo ago↗ source
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.STAT · 1mo ago↗ source
- STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drugMuch-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.STAT · 1mo ago↗ source